SCHEMBL7229895

SCHEMBL7229895

COc1cc(CBr)ccc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2E1 P05181 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP4B1 P13584 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP3A5 P20815 1/20 0.46
CYP2A7 P20853 1/20 0.46
CYP3A7 P24462 1/20 0.46
CYP2F1 P24903 1/20 0.46
CYP2C18 P33260 1/20 0.46
CYP2C19 P33261 1/20 0.46
CYP2J2 P51589 1/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4F8 P98187 1/20 0.46
CYP4A11 Q02928 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27556516 0.87 HTR7 (0.44) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL29143285 0.86 HTR7 (0.51) HTR7MAPTKDM4EKMT2AALDH1A1
SCHEMBL9937910 0.85 CA2 (0.48) CYP1A2CYP3A4CYP2D6HTR7KDM4E
SCHEMBL11672601 0.84 CYP1A2 (0.47) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL3574310 0.84 CTSA (0.50) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL7221234 0.84 HTR7 (0.57) HTR7HTR2C
SCHEMBL14165291 0.84 CYP1A1 (0.61) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL20782113 0.83 HTR7 (0.66) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL24093214 0.83 CYP1A1 (0.46) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8
SCHEMBL2570486 0.83 CSNK2A1 (0.57) CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613782-B2 For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders NOVARTIS AG (CH) 2003-09-02 US disclosed
US-6423727-B1 Certain thiol inhibitors of endothelin-converting enzyme NOVARTIS AG (CH) 2002-07-23 US disclosed
US-20020082218-A1 Certain thiol inhibitors of endothelin-converting enzyme LOMBAERT STEPHANE DE (US) 2002-06-27 US disclosed
CN-1297453-A thiol endothelin converting enzyme inhibitors NOVARTIS AG (CH) 2001-05-30 CN disclosed
EP-1073674-A1 THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME Novartis AG (CH) 2001-02-07 EP disclosed
WO-1999055726-A1 CERTAIN THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME NOVARTIS AG (CH) 1999-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082218-A1 Certain thiol inhibitors of endothelin-converting enzyme ECE1, ECE2, EDNRB CYP1A1 357/4885CYP1A2 916/4885CYP2E1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.